Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial

Reuters03-25

Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial

Clover reported additional U.S. Phase 1 data for its SCB-1019 RSV candidate in older adults previously vaccinated with GSK’s Arexvy, positioning the program for the repeat-vaccination segment.
In a head-to-head booster comparison, SCB-1019 showed a 60-80% higher trend in RSV neutralizing antibody levels versus an Arexvy booster, which could support differentiation in revaccination use.
The company said more than 40% of eligible U.S. adults ages 60+ have already received a first protein-based RSV vaccine dose, indicating a sizable potential market for booster strategies.
Clover also highlighted a combined RSV+hMPV±PIV3 vaccine candidate now in Phase 2, aiming to broaden coverage beyond RSV for older adults.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065871), on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622148520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 07:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622148520","market":"us","top_or_hot":-1,"title":"Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover reported additional U.S. Phase 1 data for its SCB-1019 RSV candidate in older adults previously vaccinated with GSK’s Arexvy, positioning the program for the repeat-vaccination segment.\n        </li>\n<li>\n          In a head-to-head booster comparison, SCB-1019 showed a 60-80% higher trend in RSV neutralizing antibody levels versus an Arexvy booster, which could support differentiation in revaccination use.\n        </li>\n<li>\n          The company said more than 40% of eligible U.S. adults ages 60+ have already received a first protein-based RSV vaccine dose, indicating a sizable potential market for booster strategies.\n        </li>\n<li>\n          Clover also highlighted a combined RSV+hMPV±PIV3 vaccine candidate now in Phase 2, aiming to broaden coverage beyond RSV for older adults.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065871), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 07:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover reported additional U.S. Phase 1 data for its SCB-1019 RSV candidate in older adults previously vaccinated with GSK’s Arexvy, positioning the program for the repeat-vaccination segment.\n        </li>\n<li>\n          In a head-to-head booster comparison, SCB-1019 showed a 60-80% higher trend in RSV neutralizing antibody levels versus an Arexvy booster, which could support differentiation in revaccination use.\n        </li>\n<li>\n          The company said more than 40% of eligible U.S. adults ages 60+ have already received a first protein-based RSV vaccine dose, indicating a sizable potential market for booster strategies.\n        </li>\n<li>\n          Clover also highlighted a combined RSV+hMPV±PIV3 vaccine candidate now in Phase 2, aiming to broaden coverage beyond RSV for older adults.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065871), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5kl6Sf:1","article_id":"2622148520","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622148520","pubTimestamp":1774395742,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clover reported additional U.S. Phase 1 data for its SCB-1019 RSV candidate in older adults previously vaccinated with GSK’s Arexvy, positioning the program for the repeat-vaccination segment.In a head-to-head booster comparison, SCB-1019 showed a 60-80% higher trend in RSV neutralizing antibody levels versus an Arexvy booster, which could support differentiation in revaccination use.The company said more than 40% of eligible U.S. adults ages 60+ have already received a first protein-based RSV vaccine dose, indicating a sizable potential market for booster strategies.Clover also highlighted a combined RSV+hMPV±PIV3 vaccine candidate now in Phase 2, aiming to broaden coverage beyond RSV for older adults.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02197":"三叶草生物-B"},"translate_title":"Clover报告SCB-1019 RSV疫苗加强剂在美国1期试验中将中和抗体GMT提高60%-80%","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":0.9},"content_text":"Clover reports SCB-1019 RSV vaccine booster raised neutralizing antibody GMT by 60%-80% in US Phase 1 trial\n    \n\n\n          Clover reported additional U.S. Phase 1 data for its SCB-1019 RSV candidate in older adults previously vaccinated with GSK’s Arexvy, positioning the program for the repeat-vaccination segment.\n        \n\n          In a head-to-head booster comparison, SCB-1019 showed a 60-80% higher trend in RSV neutralizing antibody levels versus an Arexvy booster, which could support differentiation in revaccination use.\n        \n\n          The company said more than 40% of eligible U.S. adults ages 60+ have already received a first protein-based RSV vaccine dose, indicating a sizable potential market for booster strategies.\n        \n\n          Clover also highlighted a combined RSV+hMPV±PIV3 vaccine candidate now in Phase 2, aiming to broaden coverage beyond RSV for older adults.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065871), on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622148520","isCrawlerRequest":true}